Thereby, in colorectal cancer, patients with high levels of both MAP17 and pH2AX showed better OS and DFS after radiotherapy and olaparib treatment,42 suggesting that both biomarkers should be analyzed together for the design of a personalized treatment.42,44,62 Likewise, the data extracted from our cohort showed that sarcomas with high pH2AX levels have a poor prognosis, regardless of the tumor origin. Here, PDZK1IP1 is linked to colorectal cancer.